{"organizations": [], "uuid": "3f7ced689d00c7439e5106cb1ad4e725fcb74ce0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-achieve-announces-prelim-data-from/brief-achieve-announces-prelim-data-from-cytisine-phase-i-ii-clinical-study-idUSFWN1QA020", "country": "US", "domain_rank": 408, "title": "BRIEF-Achieve Announces Prelim Data From Cytisine Phase I/II Clinical Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.831, "site_type": "news", "published": "2018-02-20T19:08:00.000+02:00", "replies_count": 0, "uuid": "3f7ced689d00c7439e5106cb1ad4e725fcb74ce0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-achieve-announces-prelim-data-from/brief-achieve-announces-prelim-data-from-cytisine-phase-i-ii-clinical-study-idUSFWN1QA020", "ord_in_thread": 0, "title": "BRIEF-Achieve Announces Prelim Data From Cytisine Phase I/II Clinical Study", "locations": [], "entities": {"persons": [{"name": "cytisine", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters) - achieve life sciences inc", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Achieve Life Sciences Inc:\n* ACHIEVE ANNOUNCES PRELIMINARY DATA FROM CYTISINE PHASE I/II MULTI-DOSE, PHARMACOKINETIC AND PHARMACODYNAMICS (PK/PD) CLINICAL STUDY\n* ACHIEVE LIFE SCIENCES INC - CYTISINE WAS WELL-TOLERATED AND REPORTED ADVERSE EVENTS WERE MOSTLY MILD AND SHORT-LIVED IN STUDY\n* ACHIEVE LIFE SCIENCES - SUBJECTS WHO DID NOT ACHIEVE ABSTINENCE HAD “SIGNIFICANT REDUCTION” IN NUMBER OF DAILY CIGARETTES SMOKED BY END OF TREATMENT\n* ACHIEVE LIFE SCIENCES INC - NO ADVERSE EVENTS WERE SEVERE, SERIOUS, OR LED TO WITHDRAWAL FROM STUDY\n* ACHIEVE LIFE SCIENCES INC - EXPECTS TO INITIATE CYTISINE PHASE 3 DEVELOPMENT PROGRAM IN MID-2018 REQUIRED FOR FDA APPROVAL OF CYTISINE IN U.S. Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T19:08:00.000+02:00", "crawled": "2018-02-21T21:44:02.015+02:00", "highlightTitle": ""}